In particular, SGLT2 inhibitors (SGLT2i) have evolved into guideline-directed medical therapy for HF with both a reduced and preserved ejection fraction, regardless of diabetes status, as demonstrated by event-driven trials such as EMPEROR-Preserved, EMPEROR-Reduced, DELIVER, and DAPA-HF [3,4,5,6,7,8,9,10]. This evidence concerns the gene SLC5A2 and hydrops fetalis.